Diasorin
DIA | XMIL
Overview
Corporate Details
- ISIN(s):
- IT0003492391 (+2 more)
- LEI:
- 8156002878BDF0EE4348
- Country:
- Italy
- Address:
- VIA CRESCENTINO, SNC, 13040 SALUGGIA
- Website:
- https://diasoringroup.com/en
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
World leaders in the lab diagnostics market, we are specialists in the immunodiagnostics and molecular diagnostics segments and active in the Licensed Technology sector The Company has been developing, producing and marketing reagent kits for laboratory diagnostics all over the world, for over 50 years. Our broad offering of diagnostic tests and Licensed Technology solutions, made available thanks to ongoing investments in research, positions us as the player with the widest range of specialty solutions in the sector and identifies the Group as the "Diagnostics Specialist". Diagnosis is the first step towards understanding a person’s state of health. This is why our tests can make the difference: they are precise and reliable and enable delivery of early diagnosis of various pathologies for millions of people who will then be able to receive the most appropriate therapy.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-08-07 11:29 |
Interim Report
Interim Financial Report as at June 30, 2025
|
English | 3.0 MB | |
2025-08-04 16:51 |
Report Publication Announcement
Pubblicazione della Relazione finanziaria semestrale al 30 giugno 2025
|
Italian | 184.4 KB | |
2025-08-04 15:32 |
Interim Report
Relazione Finanziaria Semestrale del Gruppo Diasorin al 30 giugno 2025
|
Italian | 3.4 MB | |
2025-07-31 16:24 |
Investor Presentation
Diasorin H1 2025 Results Presentation
|
English | 1.4 MB | |
2025-07-31 16:22 |
Earnings Release
Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed
|
English | 342.3 KB | |
2025-07-31 16:21 |
Earnings Release
Ricavi in crescita ed incremento della marginalità nel 1° semestre 2025. Confer…
|
Italian | 470.4 KB | |
2025-07-07 09:34 |
Regulatory News Service
Communication on total amount of voting rights
|
Italian | 210.5 KB | |
2025-07-07 09:32 |
Regulatory News Service
Comunicazione dell'ammontare complessivo dei diritti di voto
|
Italian | 232.4 KB | |
2025-07-01 08:57 |
Transaction in Own Shares
Diasorin S.p.A. - Allegato 3F
|
Italian | 91.4 KB | |
2025-05-12 15:37 |
Post-Annual General Meeting Information
Pubbicazione del verbale dell'Assemblea degli Azionisti del 28 aprile 2025
|
Italian | 184.1 KB | |
2025-05-12 15:26 |
Post-Annual General Meeting Information
Verbale Assemblea Ordinaria degli Azionisti 28 aprile 2025
|
English | 21.1 MB | |
2025-05-06 17:43 |
Investor Presentation
Diasorin Q1 2025 Results Presentation
|
English | 1.4 MB | |
2025-05-06 17:39 |
Earnings Release
Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidan…
|
English | 369.9 KB | |
2025-05-06 17:38 |
Earnings Release
Ricavi in crescita dell’8% ed EBITDA Margin al 34%: i risultati del 1° trimestr…
|
Italian | 417.5 KB | |
2025-04-29 12:52 |
Post-Annual General Meeting Information
Shareholders' Meeting April 29, 2025 - Summary report on votes
|
English | 224.5 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
Nanobiotix | France | NANO | |
|
Nanoform Finland OYJ | Finland | NANOFH | |
![]() |
NanoGroup S.A. | Poland | NNG | |
![]() |
Nattaro Labs AB | Sweden | NATTA | |
![]() |
Neovacs | France | ALNEV | |
![]() |
Newron Pharmaceuticals S.p.A. | Italy | NWRN | |
|
NextCell Pharma AB | Sweden | NXTCL | |
|
NextFerm Technologies Ltd. | Israel | NXFR | |
![]() |
NFL Biosciences | France | ALNFL | |
![]() |
Nortem BioGroup | Spain | MLBIO |